Evotec SE (EVO) Non-Current Debt (2009 - 2026)
Evotec SE (EVO) reported Non-Current Debt of $349873.8 for Q1 2026, down 20.39% on a YoY basis from $439465.7 in Q1 2025, and down 12.63% sequentially from $400440.3 in Q4 2025.
Evotec SE (EVO) Non-Current Debt (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Non-Current Debt data on file, last reported at $349873.8 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt fell 20.39% year-over-year to $349873.8; the trailing twelve-month figure through Mar 2026 stood at $349873.8 (down 20.39% YoY), and the FY2025 full-year result was $400440.3, down 99.9% from the prior year.
- Non-Current Debt slipped to $349873.8 in Q1 2026, from $400440.3 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $513.3 million in Q4 2023 to a low of -$349703.3 in Q2 2022.
- A 5-year average of $119.7 million and a median of $420776.3 in 2025 frame the typical range for Non-Current Debt.
- Across the five-year window, Non-Current Debt surged 33.99% in 2022 and plunged 99.9% in 2025, its largest moves.
- Tracing EVO's Non-Current Debt over 5 years: stood at $500.2 million in 2022, then gained by 2.62% to $513.3 million in 2023, then slipped by 18.25% to $419.7 million in 2024, then sank by 99.9% to $400440.3 in 2025, then decreased by 12.63% to $349873.8 in 2026.
- Business Quant data shows EVO's Non-Current Debt at $349873.8 in Q1 2026, $400440.3 in Q4 2025, and $453294.1 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 10.34 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 14.02 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 27.86 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 12.41 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.74 Bn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - | 349,873.83 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 349,873.83 |
| Dec 31, 2025 | 400,440.28 |
| Sep 30, 2025 | 453,294.10 |
| Jun 30, 2025 | 402,086.80 |
| Mar 31, 2025 | 439,465.75 |
| Dec 31, 2024 | 419.68 Mn |
| Sep 30, 2024 | 457,423.80 |
| Dec 31, 2023 | 513.34 Mn |
| Dec 31, 2022 | 500.22 Mn |
| Sep 30, 2022 | 329,479.85 |
| Jun 30, 2022 | -349,703.29 |
| Mar 31, 2022 | 366,012.29 |
| Dec 31, 2021 | 373.33 Mn |
| Sep 30, 2021 | 374,921.38 |
| Dec 31, 2020 | 394.67 Mn |
| Sep 30, 2010 | 3,873.82 |
| Jun 30, 2010 | 3,824.51 |
| Mar 31, 2010 | 5.01 |
| Dec 31, 2009 | 5,548.09 |
| Jun 30, 2009 | 9.87 Mn |